NCT04597541View on ClinicalTrials.gov

A Study of AK112 for Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

July 15, 2024

Conditions
Solid Tumor, Adult
Interventions
DRUG

AK112

AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT04597541 - A Study of AK112 for Advanced Solid Tumors | Biotech Hunter | Biotech Hunter